Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cognitive function in the context of pharmacogenetic CYP2D6 variability and anticholinergic burden in older adults - results from the ActiFE study.

European journal of clinical pharmacology - 4 Aug 2026

Lorenz Linda, Berres Judith, Denkinger Michael D, Rothenbacher Dietrich, Braig Stefanie, Dallmeier Dhayana, Just Katja S

Abstract excerpt

PURPOSE: To investigate the role of CYP2D6 and its pharmacogenetic variability in the association between anticholinergic burden and cognitive function in older adults. METHODS: We conducted a cross-sectional analysis of 872 community-dwelling adults ≥ 65 years from the ActiFE-Ulm cohort. Cognitive performance was assessed using the Mini-Mental State Examination (MMSE). Anticholinergic burden scores deriving from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cognition

Share to Cross-Sectional Studies

Share to Cytochrome P-450 CYP2D6

Share to Genotype

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Source

Open in PubMed Open full text

Identifiers

PMID: 42547570
DOI: 10.1007/s00228-026-04155-y
PMCID: PMC13433654

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cognitive function in the context of pharmacogenetic CYP2D6 variability and anticholinergic burden in older adults - results from the ActiFE study.PMID 42547570Read ↗

Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in DementiaSemantic proximity Read ↗

Association between inherited CYP2D6/2C19 phenotypes and anticholinergic measures in elderly patients using anticholinergic drugs.Semantic proximity Read ↗

Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?Semantic proximity Read ↗

Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disordersSemantic proximity Read ↗

Anticholinergic Drug Burden and Risk of Incident MCI and Dementia: A Population-based Study.Semantic proximity Read ↗

Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults.Semantic proximity Read ↗

Assessing the Anticholinergic Cognitive Burden Classification of Putative Anticholinergic Drugs Using ADME PropertiesSemantic proximity Read ↗

Measuring pharmacogenetics in special groups: geriatrics.Semantic proximity Read ↗

Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 VariantsSemantic proximity Read ↗

Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic ExposureSemantic proximity Read ↗

Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study.Semantic proximity Read ↗

Association between anticholinergic drugs and apolipoprotein E epsilon4 allele and poorer cognitive function in older cardiovascular patients: a cross-sectional study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.